zika
viru
zikv
mosquitoborn
flaviviru
caus
neonat
abnorm
disord
antibodi
zikv
envelop
e
protein
block
infect
studi
nextgener
sequenc
ng
immunoglobulin
heavi
chain
igh
mrna
transcript
combin
singlecel
pcr
clone
ebind
monoclon
antibodi
analys
antibodi
respons
patient
earli
stage
infect
one
year
clearanc
viru
patient
igh
repertoir
day
symptom
onset
show
dramat
domin
clonal
expans
low
clonal
divers
igh
repertoir
month
diseasefre
statu
domin
clone
increas
divers
ebind
antibodi
appear
abundantli
repertoir
earli
stage
infect
quickli
declin
clearanc
viru
certain
vh
gene
appear
preferenti
enlist
rapid
antibodi
respons
zikv
infect
antibodi
requir
rel
somat
hypermut
acquir
abil
bind
e
protein
point
possibl
mechan
rapid
defenc
zikv
infect
studi
provid
uniqu
holist
view
dynam
chang
characterist
antibodi
respons
zikv
infect
zika
viru
zikv
member
flavivirida
famili
mainli
transmit
aed
mosquito
howev
also
report
viru
transmit
sexual
contact
blood
transfus
clinic
evid
show
zikv
cross
placent
barrier
caus
microcephali
develop
foetus
neurolog
complic
adult
guillainbarr
syndrom
zikv
envelop
e
protein
mediat
viral
attach
host
cell
fusion
cell
membran
flaviviru
e
ectodomain
three
distinct
domain
ediiii
sever
zikvspecif
antibodi
isol
infect
individu
among
ebind
antibodi
especi
target
ediii
manifest
potent
neutral
activ
vitro
vivo
presenc
ediiitarget
antibodi
correl
serumneutr
activ
zikv
human
adapt
immun
system
consist
b
cell
play
import
role
defens
infect
success
antibodi
respons
reli
gener
divers
repertoir
b
cell
receptor
bcr
bcr
membranebound
antigenbind
immunoglobulin
ig
like
antibodi
compos
two
immunoglobulin
heavi
chain
two
light
chain
bcr
divers
achiev
rearrang
variabl
v
divers
join
j
gene
segment
immunoglobulin
heavi
chain
locu
igh
v
j
gene
segment
light
chain
locu
igk
b
cell
activ
upon
encount
antigen
bind
bcr
b
cell
encount
antigen
recruit
local
lymph
follicl
undergo
process
call
somat
hypermut
shm
increas
antigenspecif
affin
germin
centr
shm
occur
specif
region
complementari
determin
region
cdr
critic
antigen
bind
cdr
divid
three
subregion
typic
play
key
role
determin
antibodi
specif
affin
therefor
sequenc
often
use
lineag
structur
analysi
antibodi
repertoir
activ
b
cell
prolifer
differenti
gener
popul
antibodysecret
plasma
b
cell
memori
b
cell
antigenspecif
memori
b
cell
human
peak
day
infect
vaccin
account
approxim
b
cell
peripher
blood
memori
b
cell
differenti
longliv
memori
b
cell
mediat
rapid
recal
respons
longliv
plasma
cell
maintain
antibodi
product
recent
nextgener
sequenc
ng
base
antibodi
repertoir
analysi
use
provid
system
view
humor
respons
antigen
stimuli
viral
infect
vaccin
understand
mechan
dynam
underli
antibodi
gener
facilit
vaccin
design
improv
prognosi
infecti
diseas
report
isol
ebind
mab
zikvinfect
patient
perform
ng
analysi
igh
mrna
repertoir
gain
insight
dynam
antibodi
respons
infect
patient
male
return
guangzhou
venezuela
februari
hospit
guangzhou
peopl
hospit
guangzhou
china
zikv
rna
detect
serum
saliva
urin
sampl
rtpcr
patient
manifest
rel
mild
symptom
includ
fever
rash
sore
throat
fatigu
zikv
longer
detect
patient
urin
day
symptom
onset
recov
complet
discharg
hospit
approxim
three
week
patient
test
serolog
neg
indic
previou
exposur
whole
blood
sampl
measur
ml
contain
million
mononuclear
cell
collect
patient
day
respect
edta
anticoagulantcontain
tube
peripher
blood
mononuclear
cell
pbmc
isol
densiti
gradient
separ
ficollhypaqu
gradient
ge
healthcar
chicago
il
usa
plasma
sampl
heatinactiv
min
prior
aliquot
storag
studi
conduct
accord
rule
regul
stipul
chines
govern
protect
human
subject
furthermor
patient
provid
written
inform
consent
approv
use
blood
sampl
present
studi
singl
b
cell
sort
rtpcr
sequenc
clone
express
mab
freshli
isol
pbmc
stain
cocktail
follow
antibodi
antihuman
invitrogenthermo
fisher
scientif
carlsbad
ca
usa
bd
bioscienc
san
jose
ca
usa
antihisp
miltenyi
biotec
bergisch
gladbach
germani
zikv
e
protein
cat
sino
biolog
inc
beij
china
use
probe
isol
zikv
especif
memori
b
cell
igg
memori
b
cell
sort
use
multilas
bd
ii
cell
sorter
bd
bioscienc
individu
b
cell
sort
pcr
plate
contain
lysi
buffer
per
cell
lysi
buffer
contain
inhibitor
promega
madison
wi
usa
firststrand
buffer
dtt
igep
sigmaaldrich
st
loui
mo
usa
pcr
plate
contain
sort
cell
frozen
dri
ice
store
use
revers
transcript
rt
rtpcr
perform
ig
gene
clone
express
vector
describ
previous
briefli
rt
carri
ad
random
hexam
promega
dntp
mm
superscript
iii
invitrogen
well
follow
incub
h
igg
heavi
light
chain
variabl
region
independ
amplifi
nest
pcr
first
round
pcr
perform
cdna
directli
follow
rt
hotstartaq
plu
dna
polymeras
qiagen
hilden
germani
primer
mixtur
pcr
perform
follow
cycl
min
cycl
round
round
min
follow
min
cool
pcr
product
evalu
agaros
gel
region
display
band
expect
size
nearli
bp
heavi
chain
kappalambda
chain
respect
excis
gel
sent
sanger
sequenc
purif
human
antibodi
sequenc
analys
use
imgtvquest
http
wwwimgt
org
fulllength
express
cotransfect
cell
equal
quantiti
pair
heavi
light
chain
plasmid
base
backbon
pcineo
vector
cultur
media
harvest
four
day
transfect
purifi
use
protein
agaros
ge
healthcar
nunc
maxisorp
plate
thermo
fisher
scientif
waltham
usa
coat
zikv
e
ediii
protein
incub
overnight
block
h
plate
incub
cultur
media
contain
antibodi
dilut
serial
dilut
purifi
mab
block
buffer
plate
wash
six
time
phosphatebuff
salin
pb
secondari
antibodi
goat
antihuman
igg
cat
abcam
cambridg
uk
appli
dilut
block
solut
plate
incub
h
tmb
substrat
ad
absorb
measur
nm
biotek
synergi
htx
multimod
reader
winooski
vt
usa
neutral
activ
antibodi
measur
use
flow
cytometrybas
neutral
assay
vero
cell
describ
previous
briefli
cell
plate
plate
h
conduct
analysi
mab
serial
dilut
incub
mem
gibcothermo
fisher
scientif
contain
fb
gibco
cell
infect
mixtur
h
co
shake
everi
min
mlwell
mem
medium
contain
fb
ad
incub
addit
h
infect
cell
collect
trypsin
fix
permeabil
incub
fixat
permeabil
solut
bd
bioscienc
ice
min
next
cell
stain
ml
antibodi
dilut
bd
buffer
cat
bd
bioscienc
stain
dilut
antimous
igg
fitc
ice
min
wash
percentag
eposit
cell
measur
use
bd
ii
pbmc
isol
whole
blood
sampl
collect
day
symptom
onset
total
rna
extract
use
ls
reagent
accord
manufactur
protocol
invitrogen
armspcr
use
multiplex
primer
irepertoir
inc
huntsvil
al
usa
perform
amplifi
igh
repertoir
sequenc
describ
previous
briefli
multiplex
primer
cover
nearli
human
vh
gene
forward
primer
constant
region
primer
cover
five
antibodi
isotyp
revers
primer
design
forward
primer
fi
forwardin
revers
primer
ri
reversein
also
includ
illumina
pairedend
sequenc
commun
primer
b
respect
illumina
san
diego
ca
usa
pcr
amplif
firstround
pcr
product
use
templat
second
round
pcr
reaction
illumina
sequenc
use
commun
primer
b
uniqu
barcod
introduc
first
round
constant
region
primer
use
distinguish
sampl
gel
purif
use
gel
extract
kit
cat
qiagen
result
product
pool
highthroughput
pairedend
sequenc
illumina
hiseq
sequenc
novogen
china
zikv
genom
sequenc
zikv
strain
current
circul
south
america
zikv
strain
isol
patient
studi
zikv
isol
blood
plasma
urin
infect
patient
viru
passag
one
time
suckl
mous
brain
cultur
vero
cell
prepar
stock
store
use
denvi
hawaii
strain
prepar
vero
cell
recombin
zikv
e
ediii
protein
cat
purchas
sino
biolog
inc
beij
china
e
protein
deriv
zikv
strain
isol
brazil
denvi
ediii
protein
cat
also
purchas
sino
biolog
illumina
bp
pairedend
read
extract
accord
uniqu
barcod
end
read
correspond
igh
constant
region
barcodematch
read
separ
assembl
base
overlap
region
use
flash
sequenc
nucleotid
submit
imgthighvquest
http
wwwimgtorghighvquest
identifi
v
j
gene
sequenc
also
analys
inhous
implement
igblast
http
wwwncbinlmnihgovigblast
verifi
accuraci
imgthighvquest
result
nonproduct
sequenc
either
stop
codon
outoffram
ighj
exclud
analysi
ig
isotyp
proport
global
vh
gene
usag
calcul
use
r
packag
alakazam
determin
whether
igh
repertoir
contain
sequenc
relat
antibodi
clone
first
identifi
sequenc
share
vh
jh
gene
segment
appli
cdhit
find
sequenc
ident
sequenc
clone
antibodi
track
ontolog
develop
isol
antibodi
longitudin
sequenc
ident
rel
isol
antibodi
measur
via
mafft
valu
diverg
germlin
vh
gene
calcul
accord
imgthighvquest
result
identitydiverg
plot
gener
describ
wu
et
al
treemap
analysi
calcul
perform
describ
yang
et
al
draw
treemap
repertoir
set
rectangl
correspond
distinct
v
gene
segment
entir
repertoir
drawn
follow
set
vj
rectangl
within
v
gene
rectangl
final
within
vj
rectangl
rectangl
repres
distinct
combin
creat
rectangl
order
largest
bottom
right
side
smallest
top
left
side
therefor
rectangl
repres
cluster
nucleotid
sequenc
v
gene
j
gene
ident
size
individu
rectangl
proport
rel
frequenc
combin
sequenc
differ
rectangl
display
differ
randomli
gener
colour
top
frequent
sequenc
igh
transcript
use
treemap
divers
index
measur
divers
immun
repertoir
j
repres
total
number
repres
uniqu
rank
domin
configur
abund
abund
repres
r
r
abund
second
abund
forth
c
minimum
number
distinct
total
sequenc
read
accordingli
calcul
follow
equat
result
ebind
mab
neutral
activ
zikv
clone
memori
b
cell
zikvinfect
patient
use
singlecel
pcr
amplif
immunoglobulin
heavi
light
chain
clone
e
proteinbind
mab
memori
b
cell
zikvinfect
patient
day
symptom
onset
tabl
figur
memori
b
cell
isol
use
zikv
e
protein
probe
fourteen
ebind
mab
includ
five
seven
ediiitarget
mab
nine
twentyfour
ediiitarget
mab
demonstr
neutral
activ
concentr
lower
zikv
strain
cellbas
neutral
assay
tabl
seven
mab
bound
ediii
indic
ediiitarget
antibodi
detail
character
ebind
mab
describ
previous
igh
repertoir
show
dramat
domin
clonal
expans
earli
stage
infect
recess
steadi
state
six
month
understand
dynam
antibodi
respons
zikv
infect
individu
use
irepertoir
armspcr
primer
unbias
amplif
igh
mrna
transcript
pbmc
million
igh
sequenc
read
obtain
sampl
timepoint
ng
use
illumina
hiseq
sequenc
figur
sampl
collect
patient
serolog
confirm
denv
infect
repertoir
contain
highest
percentag
igg
transcript
account
total
decreas
total
day
respect
contrast
igm
transcript
lowest
repertoir
account
total
respect
howev
igm
transcript
increas
day
respect
expect
ige
abund
low
time
point
interestingli
igd
iga
transcript
underw
transient
increas
day
figur
obtain
holist
view
antibodi
repertoir
dynam
time
construct
four
treemap
repres
frequent
uniqu
sequenc
day
figur
rectangl
treemap
repres
uniqu
size
proport
rel
abund
individu
sequenc
timepoint
day
igh
repertoir
appear
contain
mani
domin
clone
demonstr
presenc
mani
larg
rectangl
correspond
treemap
igh
repertoir
continu
show
clonal
expans
least
day
treemap
repertoir
similar
repertoir
appear
differ
treemap
repertoir
domin
clone
content
antibodi
repertoir
recess
day
day
demonstr
far
fewer
larg
rectangl
repertoir
notabl
zikv
rna
detect
patient
urin
day
diseas
onset
undetect
day
figur
treemap
repertoir
similar
repertoir
indic
antibodi
respons
zikv
ceas
day
figur
assess
igh
repertoir
divers
calcul
divers
index
reflect
degre
clonal
divers
valu
day
day
lowest
respect
valu
increas
day
day
figur
evid
lower
antibodi
divers
earli
stage
infect
obtain
calcul
rel
abund
uniqu
sequenc
among
total
read
rel
abund
uniqu
sequenc
lower
repertoir
repertoir
figur
taken
togeth
result
illustr
antibodi
repertoir
larg
commit
respond
viru
zikv
infect
last
least
day
howev
zikv
threat
antibodi
repertoir
recess
quiescent
steadi
state
fewer
domin
clone
greater
clonal
divers
ebind
antibodi
employ
divers
vh
gene
preferenti
enlist
sever
vh
gene
rapid
respons
zikv
infect
analys
igh
sequenc
ebind
mab
clone
mab
deriv
differ
vh
gene
tabl
assess
frequenc
global
vh
gene
usag
igh
repertoir
day
figur
frequenc
vh
gene
use
gener
correspond
igh
sequenc
rank
high
low
base
sequenc
data
igh
repertoir
sinc
day
last
timepoint
collect
patient
recov
assum
correspond
repertoir
reflect
quiescent
state
inde
frequenc
global
vh
gene
usag
repertoir
appear
similar
repertoir
suggest
antibodi
repertoir
nearli
reach
quiescent
state
day
figur
contrast
frequenc
global
vh
gene
usag
day
differ
day
day
notabl
sever
vh
gene
appear
frequent
use
day
determin
whether
vh
gene
preferenti
enlist
respond
zikv
infect
group
vh
gene
usag
ebind
mab
clone
figur
tabl
among
vh
gene
gener
ebind
mab
highest
represent
contribut
mab
among
mab
clone
frequenc
global
usag
highest
repertoir
coincid
fact
contribut
ebind
mab
clone
figur
howev
frequenc
usag
repertoir
appear
return
basal
level
respect
also
somewhat
higher
frequenc
usag
contribut
ebind
mab
interestingli
although
extrem
low
frequenc
global
usag
repertoir
usag
transient
increas
fivefold
repertoir
figur
indic
transient
activ
respons
zikv
infect
inde
also
higher
represent
among
ebind
mab
clone
figur
given
extrem
low
frequenc
global
usag
noninfect
state
reservoir
contrast
vh
gene
frequent
use
antibodi
respons
influenza
viru
infect
contribut
ebind
mab
clone
despit
fact
rel
high
frequenc
global
usag
repertoir
repertoir
ebind
mab
higher
shm
rate
averag
shm
rate
vh
genederiv
igh
sequenc
analys
global
shm
rate
igm
igg
repertoir
global
shm
rate
igm
sequenc
highest
repertoir
decreas
day
thereaft
global
shm
rate
igg
sequenc
day
increas
day
slightli
decreas
day
figur
also
analys
shm
rate
ebind
mab
compar
rate
correspond
vh
genederiv
igh
sequenc
repertoir
tabl
averag
shm
rate
ebind
mab
chang
amino
acid
averag
interestingli
averag
shm
rate
ediiitarget
mab
chang
amino
acid
averag
next
compar
shm
rate
mab
igh
sequenc
deriv
vh
gene
repertoir
figur
shm
rate
ebind
mab
includ
ediiitarget
mab
higher
averag
shm
rate
igh
sequenc
deriv
vh
gene
figur
notabl
averag
shm
rate
mab
averag
shm
rate
mab
lower
averag
shm
rate
igh
sequenc
deriv
figur
tabl
result
indic
ebind
antibodi
includ
ediiitarget
antibodi
could
gener
without
high
shm
rate
suggest
potenti
mechan
rapid
respons
zikv
infect
search
presenc
igh
sequenc
reservoir
vj
gene
combin
sequenc
ident
ebind
mab
clone
figur
estim
adult
person
approxim
ml
blood
sinc
b
cell
sequenc
isol
ml
peripher
blood
b
cell
harbour
sequenc
may
miss
limit
blood
sampl
volum
obtain
surpris
ebind
mab
vj
sequenc
found
repertoir
wherea
mab
sequenc
found
repertoir
respect
figur
result
indic
b
cell
produc
ebind
antibodi
abundantli
present
peripher
blood
soon
infect
b
cell
quickli
disappear
clearanc
zikv
infect
import
note
ebind
mab
clone
memori
b
cell
pbmc
collect
day
next
perform
twodimension
identitydiverg
analysi
search
igh
lineag
sequenc
three
repres
mab
repertoir
correspond
time
point
three
mab
neutral
antibodi
sequenc
found
day
thereaft
indic
mab
abund
day
figur
igh
lineag
sequenc
highli
homolog
mab
found
repertoir
repertoir
igh
sequenc
highli
homolog
mab
found
repertoir
figur
note
mab
low
shm
rate
respect
verifi
whether
chang
ebind
mab
close
relat
sequenc
igh
reservoir
correl
presenc
ebind
antibodi
patient
serum
measur
titr
eand
ediiibind
antibodi
neutral
activ
serum
sampl
collect
day
onset
symptom
figur
titr
ebind
antibodi
highest
level
day
decreas
day
result
line
dynam
chang
igh
repertoir
reveal
treemap
show
domin
clonal
expans
day
figur
therefor
mani
clone
appear
emerg
respons
zikv
infect
notabl
zikv
neutral
activ
ediiitarget
antibodi
highest
level
day
declin
day
onward
figur
result
correl
well
ng
analysi
neutral
igh
sequenc
repertoir
among
ebind
mab
relat
sequenc
found
repertoir
neutral
mab
ediiitarget
mab
figur
howev
sequenc
neutral
mab
ediiitarget
mab
found
repertoir
furthermor
sequenc
one
neutral
mab
ediiibind
mab
found
repertoir
figur
observ
suggest
ediiibind
antibodi
well
neutral
antibodi
like
reced
quickli
ediiibind
antibodi
patient
studi
ng
igh
mrna
transcript
pbmc
combin
singlecel
clone
zikv
ebind
antibodi
use
analys
igh
repertoir
patient
meantim
heavi
light
chainpair
ebind
mab
clone
memori
b
cell
collect
day
onset
symptom
notabl
near
half
ebind
mab
exhibit
neutral
activ
zikv
ng
data
analys
combin
studi
ebind
mab
neutral
mab
present
holist
view
antibodi
repertoir
draw
treemap
reveal
dynam
chang
antibodi
respons
zikv
infect
wartim
aftermath
first
two
month
zikv
infect
dramat
expans
domin
b
cell
clone
respons
zikv
infect
therefor
clonal
divers
lower
peacetim
six
month
one
year
diseas
antibodi
repertoir
recess
state
involv
domin
b
cell
clone
greater
b
cell
clonal
divers
given
heavi
chain
antibodi
play
key
role
antibodi
bind
contribut
light
chain
assess
present
studi
howev
may
constitut
worthwhil
investig
futur
import
note
patient
verifi
denvneg
sampl
collect
show
crossreact
denv
e
protein
serum
sampl
collect
two
month
two
year
postzikv
infect
indic
individu
denv
infect
prior
primari
zikv
infect
infer
individu
manifest
denv
infect
recoveri
zikv
infect
igh
repertoir
would
like
reveal
chang
dramat
expans
domin
b
cell
clone
respons
new
infect
howev
igh
repertoir
day
day
show
fewer
domin
b
cell
clone
higher
clonal
divers
igh
repertoir
day
day
heavi
chain
plot
function
sequenc
similar
templat
sequenc
diverg
put
germlin
gene
xaxi
repres
percentag
divers
vh
gene
germlin
sequenc
shown
heatmap
indic
colour
c
serum
sampl
collect
day
diseas
onset
bind
activ
zikv
e
ediii
neutral
activ
zikv
strain
determin
one
limit
studi
antibodi
repertoir
igh
mrna
transcript
obtain
origin
blood
sampl
repres
small
fraction
total
blood
present
human
bodi
uniqu
sequenc
repres
b
cell
clone
b
cell
contain
exact
lineag
igh
sequenc
may
miss
blood
sampl
collect
although
imposs
live
subject
complet
antibodi
repertoir
ideal
come
sequenc
b
cell
individu
studi
demonstr
even
ml
peripher
blood
provid
insight
inform
antibodi
respons
among
ebind
mab
clone
singl
individu
mab
sequenc
could
found
repertoir
wherea
mab
sequenc
could
found
repertoir
respect
find
demonstr
b
cell
express
ebind
mab
close
relat
lineag
clone
present
soon
zikv
infect
recent
analysi
serum
antibodi
epitop
repertoir
zikvinfect
patient
also
reveal
ebind
ediiitarget
antibodi
present
earli
even
day
symptom
onset
matur
increas
affin
earli
day
symptom
onset
result
support
ng
analysi
b
cell
express
ebind
ediiitarget
antibodi
abundantli
present
soon
zikv
infect
analysi
neutral
mab
reveal
mostli
present
alongsid
lineag
diverg
clone
day
day
observ
suggest
primari
zikv
infect
b
cell
contain
divers
vh
gene
underw
rapid
clonal
expans
upon
stimul
zikv
antigen
b
cell
express
ebind
antibodi
appear
earli
present
abund
antibodi
repertoir
transient
decreas
igh
clonal
divers
indic
antibodi
respons
larg
modul
defend
intrud
zikv
howev
upon
clearanc
viru
antibodi
repertoir
gradual
recess
quiescent
steadi
state
domin
b
cell
clone
greater
divers
confer
effect
prepar
potenti
infect
anoth
find
studi
igh
sequenc
ebind
mab
includ
ediiitarget
mab
rel
low
shm
rate
shm
rate
ebind
mab
ediiitarget
mab
higher
averag
shm
rate
correspond
vh
genederiv
igh
sequenc
figur
human
antibodi
low
shm
rate
zikv
report
previous
lack
investig
one
group
report
clone
germlinelik
mab
use
phage
display
human
antibodi
librari
anoth
group
report
panel
germlinelik
antibodi
clone
circul
plasmablast
zikvinfect
patient
day
symptom
onset
mab
exhibit
weaktomoder
neutral
potenc
one
mab
shm
capac
could
nevertheless
bind
immunodomin
epitop
neutral
zikv
ebind
mab
clone
includ
ediiitarget
mab
low
shm
rate
figur
would
ideal
could
obtain
pbmc
patient
infect
howev
would
imposs
predict
infect
prior
infect
nevertheless
gather
pbmc
day
could
consid
infect
state
base
ng
analysi
igh
repertoir
obtain
frequenc
global
vh
gene
usag
subject
earli
infect
one
year
recoveri
divers
vh
gene
use
gener
ebind
mab
ie
vh
gene
contribut
mab
clone
memori
b
cell
howev
sever
vh
gene
high
frequenc
global
vh
gene
usag
timepoint
high
frequenc
represent
among
ebind
mab
contribut
gene
particularli
interest
gener
popul
low
frequenc
global
vh
gene
usag
patient
studi
although
low
frequenc
global
usag
averag
repertoir
usag
day
zikv
infect
transient
elev
fivefold
sinc
high
percentag
represent
among
ebind
mab
low
shm
rate
tabl
propos
like
preferenti
enlist
rapid
respons
zikv
infect
patient
rapid
respons
requir
low
level
shm
activ
therefor
antibodi
requir
long
matur
process
achiev
affin
studi
three
mab
low
shm
rate
rang
figur
tabl
zikv
specif
mab
deriv
also
report
patient
respons
zikv
infect
instanc
anoth
group
report
frequent
use
zikvspecif
antibodi
denvzikv
crossinfect
patient
primari
zikvinfect
patient
comparison
high
frequenc
global
usag
contribut
ebind
mab
clone
among
zikv
ebind
mab
report
research
also
rare
use
sinc
frequent
use
antibodi
influenza
viru
like
preferenti
enlist
respond
pathogen
like
influenza
viru
zikv
studi
combin
singl
b
cell
antibodi
clone
longitudin
analysi
igh
repertoir
patient
found
sever
vh
gene
appear
preferenti
enlist
rapid
gener
ebind
antibodi
zikv
infect
mab
low
shm
rate
also
isol
patient
infect
ebola
viru
rsv
merscov
antibodi
larg
number
shm
requir
frequent
antigen
encount
helper
cell
germin
centr
propos
mechan
rapid
defenc
zikv
infect
gener
manifest
short
diseas
cours
certain
vh
gene
preferenti
select
gener
zikvspecif
antibodi
without
need
undergo
long
matur
process
person
expos
zikv
infect
primari
b
cell
respons
b
cell
rapidli
gener
zikvspecif
antibodi
includ
neutral
antibodi
requir
accumul
larg
number
shm
preferenti
usag
vh
gene
may
attribut
evolut
mani
year
interact
homo
sapien
zikv
along
flavivirus
longitudin
analysi
igh
repertoir
corrobor
well
result
singl
b
cell
antibodi
clone
neutral
ebind
ediiibind
activ
serum
sampl
collect
day
studi
show
ediiitarget
antibodi
igh
reservoir
correl
well
serumneutr
activ
zikv
result
also
line
report
presenc
ediiitarget
antibodi
correl
serumneutr
activ
zikv
studi
also
indic
ebind
antibodi
persist
longer
ediiibind
antibodi
neutral
antibodi
patient
impli
ediand
ediibind
antibodi
may
last
longer
patient
sinc
ediand
ediibind
antibodi
lowneutr
activ
may
play
role
antibodymedi
enhanc
infect
flavivirus
share
similar
epitop
would
worthwhil
studi
larg
cohort
sampl
futur
studi
provid
insight
antibodi
respons
zikv
infect
implic
design
develop
vaccin
zikv
